Navigation Links
Rigel to Present at the 2008 Credit Suisse Healthcare Conference
Date:11/11/2008

SOUTH SAN FRANCISCO, Calif., Nov. 11 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, Rigel's president and chief executive officer, will present a company overview at the 2008 Credit Suisse Healthcare Conference on Thursday, November 13 at 4:30 p.m. MST. The conference will be held at the Arizona Biltmore Resort in Phoenix, Arizona.

To access the live audio webcast or the subsequent archived recording, log on to http://www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.

About Rigel (http://www.rigel.com)

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and cancer, as well as viral and metabolic diseases. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. Rigel has product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.

Contact: Ryan Maynard

Phone: 650.624.1284

Email: invrel@rigel.com


'/>"/>
SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Rigel Announces Third Quarter 2008 Financial Results and Clinical Update
2. Rigel to Host Update Conference Call
3. Rigel Announces Fourth Quarter and Year End 2007 Financial Results
4. Rigel to Present at BIO CEO & Investor Conference
5. Rigel Announces Pricing of Public Offering of Common Stock
6. Rigel to Present Research Programs at Scientific Conferences
7. Rigel to Present at BIO Investor Forum 2007
8. Interleukin Genetics to Present New Findings on Osteoporosis at the 58th Annual Meeting of the American Society of Human Genetics
9. Cynvec LLC(SM) to Present at the Rodman & Renshaw 10th Annual Healthcare Conference on November 11, 2008
10. Synvista Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
11. Genmab A/S: Ofatumumab Pivotal CLL Data to be Presented at ASH
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... Nov. 21, 2014  The element of surprise has ... i.e., they strike without warning. Until now, epidemiologists had ... a viral outbreak, resulting in suboptimal responses to both ... Photo - http://photos.prnewswire.com/prnh/20141121/160242 ... been removed because virus gene structural changes have been ...
(Date:11/21/2014)... The science of light and how it ... than 200 primary students in a traveling program organized ... Otago Physics Department and funded by an SPIE ... the university’s OSA/SPIE Student Chapter visited six primary schools ... from small, rural schools hands-on lessons in optics and ...
(Date:11/21/2014)... The report, "Synthetic Biology Market by ... Technology (Bioinformatics, Nanotechnology, Gene Synthesis, Cloning & ... Global Forecast to 2018", analyses and studies ... challenges. , Browse 99 market data tables ... and in-depth TOC of the global synthetic ...
(Date:11/21/2014)... (PRWEB) November 21, 2014 2014 ... Ferrocyanide Industry” is a professional and in-depth research ... Sodium ferrocyanide information, like its definition, classification, ... industry overview. This report covers the international market ... global (such as the US, Europe, Asia, China, ...
Breaking Biology Technology:Viruses' Advantage of Surprise is Lost 2Optics and photonics outreach programs share science, spark fascination with light 2Optics and photonics outreach programs share science, spark fascination with light 3Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 2Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 3Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 4Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 2Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 3
... Promises to Revolutionize Food Processing, ... ENW) ("EnWave" or "the Company") today announced that ... continuous nutraREV(TM) food dehydration equipment to CAL-SAN Enterprises, ... largest blueberry producers. With this sale, EnWave has ...
... of "In the Zone for UC" Campaign, Centocor Ortho ... Colitis Foundation of America for Each Point Pisani Scores ... Ortho Biotech Inc. announced today a partnership with professional ... colitis (UC) and funding to support continued education and ...
... Colo., March 2 Accera, Inc., ... nervous system (CNS) diseases, today launched Axona(TM) in ... is a first-in-class medical food for the clinical ... mild-to-moderate Alzheimer,s. Dispensed by prescription, it targets the ...
Cached Biology Technology:EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology 2EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology 3EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology 4Pro Hockey Player Fernando Pisani Looks to Shoot and Score Against Ulcerative Colitis 2Pro Hockey Player Fernando Pisani Looks to Shoot and Score Against Ulcerative Colitis 3Pro Hockey Player Fernando Pisani Looks to Shoot and Score Against Ulcerative Colitis 4Video: Accera Launches Axona(TM), First Medical Food Therapy to Help Manage Mild-to-Moderate Alzheimer's Disease 2Video: Accera Launches Axona(TM), First Medical Food Therapy to Help Manage Mild-to-Moderate Alzheimer's Disease 3Video: Accera Launches Axona(TM), First Medical Food Therapy to Help Manage Mild-to-Moderate Alzheimer's Disease 4
(Date:11/15/2014)... , Nov. 13, 2014  While we may still ... Doctor McCoy used in "Star Trek" to gain instant access ... designed to work with smartphones and tablets for monitoring and ... the healthcare world. This may seem a tad Orwellian to ... to adopt some of these technological opportunities into their healthcare ...
(Date:11/7/2014)... , Nov. 7, 2014  In conjunction with the ... Police Departments, The Community Foundation of the Verdugos has announced ... DNA JUSTICE PROJECT," a $250,000 initiative to keep the Verdugo ... In its first six months of existence, the Lab has ... support for local law enforcement. "Because our number ...
(Date:11/6/2014)... Insilico Medicine, Inc, a Baltimore-based bioinformatics company focused ... announced a research collaboration with the international leader ... (OTC: CSBR). , "There are many companies utilizing ... Oncology,s TumorGraft technology is unique in a way ... generating vast amounts of valuable data. Our bioinformatic ...
Breaking Biology News(10 mins):Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2
... NEW ... uplinks from satellite transmitters fitted on penguins, albatrosses, sea lions, and ... have released the first-ever atlas of the Patagonian Sea a ... ...
... CORVALLIS, Ore. An accidental discovery in a laboratory ... over thousands of years has absorbed the energies of ancient ... the creation of a near-perfect blue pigment. Through ... sought inorganic compounds that could be used to paint things ...
... the Max Delbrck Center for Molecular Medicine (MDC) Berlin-Buch ... DNA damage. Dr. Michael Stilmann, Dr. Michael Hinz and ... which detects DNA damage within seconds, activates the transcription ... triggers a survival program, which blocks programmed cell death. ...
Cached Biology News:Penguins and sea lions help produce new atlas 2Accidental discovery produces durable new blue pigment for multiple applications 2How cells tolerate DNA damage -- start signal for cell survival program identified 2How cells tolerate DNA damage -- start signal for cell survival program identified 3
Umbilical cord blood CD14+ Monocytes, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Monocytes, B Cells and NK Cells...
Umbilical cord blood basophils, For immunohistochemistry (IHC)...
Human peripheral blood neutrophils, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Granulocytes...
Human peripheral blood CD14+ monocytes, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Monocytes, B Cells, NK Cells and Stem Cells...
Biology Products: